Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 


Ligand for TLR7 and TLR8
ALX-420-038-M005 5 mg 62.00 USD
ALX-420-038-M025 25 mg 247.00 USD
Do you need bulk/larger quantities?
R-848 is a selective ligand for Toll-like receptor 7 (TLR7) in mouse and for TLR7 and TLR8 in human. Potent antitumor and antiviral compound. Stimulates antibody secretion, cytokine production, protection from apoptosis and CD80 upregulation.

Product Specification

Alternative Name:4-Amino-2-(ethoxymethyl)-a,a-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol, S 28463, Resiquimod
Purity:≥98% (HPLC)
Identity:Identity determined by MS, 1H-NMR and 13C-NMR.
Endotoxin Content:Endotoxin-free
Appearance:White to off-white solid.
Solubility:Soluble in DMSO, dichloromethane, 100% or 5% methanol; poorly soluble in acetonitrile or ethyl acetate.
Long Term Storage:-20°C
Please mouse over

Product Literature References

The TLR7 ligand R848 prevents mouse graft-versus-host disease and cooperates with anti-interleukin-27 antibody for maximal protection and regulatory T-cell upregulation: M. Gaignage, et al.; Haematologica 104, 392 (2019), Abstract; Full Text
The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer: K.A. Michaelis, et al.; Nat. Commun. 10, 4682 (2019), Abstract; Full Text
Assessment of lung cell toxicity of various gasoline engine exhausts using a versatile in vitro exposure system: C. Bisig, et al.; Environ. Pollut. 235, 263 (2018), Abstract;
N-methyl-D-aspartate receptor antibody production from germinal center reactions: Therapeutic implications: M. Makuch, et al.; Ann. Neurol. 83, 553 (2018), Abstract; Full Text
Polymer-based nanoparticles loaded with a TLR7 ligand to target the lymph node for immunostimulation: J. Widmer, et al.; Int. J. Pharm. 535, 444 (2018), Abstract;
Adjuvanting an SIV vaccine with TLR ligands encapsulated in nanoparticles induces persistent antibody responses and enhanced protection in TRIM5α restrictive macaques: S.P. Kasturi, et al.; J. Virol. 91, e01844 (2017), Abstract;
Ligation of CD180 inhibits IFN-α signaling in a Lyn-PI3K-BTK-dependent manner in B cells: M. You, et al.; Cell. Mol. Immunol. 14, 192 (2017), Application(s): Cell culture, Abstract;
Activation of TLR7 increases CCND3 expression via the downregulation of miR-15b in B cells of systemic lupus erythematosus: D. Ren, et al.; Cell. Mol. Immunol. 13, 746 (2016), Application(s): Cell Culture, Abstract;
Ly6C+ monocyte efferocytosis and cross-presentation of cell-associated antigens: S.R. Larson, et al.; Cell Death Differ. 23, 997 (2016), Application(s): Efferocytosis assay, in vivo studies, Abstract; Full Text
NLRP3 activation and mitosis are mutually exclusive events coordinated by NEK7, a new inflammasome component: H. Shi, et al.; Nat. Immunol. 17, 250 (2016), Application(s): Stimulation of human monocytes, Abstract;
Notch-Hes-1 axis controls TLR7-mediated autophagic death of macrophage via induction of P62 in mice with lupus: X. Li, et al.; Cell Death Dis. 7, e2341 (2016), Application(s): Ligand contribution to macrophage death in an autophagy-dependent way, Abstract; Full Text
Toll-like receptor 3 adjuvant in combination with virus-like particles elicit a humoral response against HIV: E. Poteet, et al.; Vaccine 34, 5886 (2016), Application(s): Cell culture for VesiVax CALV TLR formulations, Abstract;
A porcine reproductive and respiratory syndrome virus (PRRSV) vaccine candidate based on the fusion protein of PRRSV glycoprotein 5 and the Toll-like Receptor-5 agonist Salmonella Typhimurium FljB: D. Xiong, et al.; BMC Vet. Res. 11, 121 (2015), Application(s): Intraperitoneal Immunization, Abstract; Full Text
Evaluation of a biodegradable microparticulate polymer as a carrier for Burkholderia pseudomallei subunit vaccines in a mouse model of melioidosis: K.L. Schully, et al.; Int. J. Pharm. 495, 849 (2015), Application(s): Cell Culture, Abstract;
Identification and Immune Functional Characterization of Pigeon TLR7: D. Xiong, et al.; Int. J. Mol. Sci. 16, 8364 (2015), Application(s): Injection into pigeons, Abstract; Full Text
Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release: P.O. Ilyinskii, et al.; Vaccine 32, 2882 (2014), Abstract;
B1 cells are unaffected by immune modulatory treatment in remitting-relapsing multiple sclerosis patients: D. Rovituso, et al.; J. Neuroimmunol. 272, 86 (2014), Abstract;
Monocytes from Chronic HBV Patients React In Vitro to HBsAg and TLR by Producing Cytokines Irrespective of Stage of Disease: A. Boltjes, et al.; PLoS One 9, e97006 (2014), Abstract; Full Text
Myeloid-specific Rictor deletion induces M1 macrophage polarization and potentiates in vivo pro-inflammatory response to lipopolysaccharide: W.T. Festuccia, et al.; PLoS One 9, e95432 (2014), Abstract; Full Text
Soluble CEACAM8 interacts with CEACAM1 inhibiting TLR2-triggered immune responses: B.B. Singer, et al.; PLoS One 9, e94106 (2014), Abstract;
Cathepsin K is involved in development of psoriasis-like skin lesions through TLR-dependent Th17 activation: T. Hirai, et al.; J. Immunol. 190, 4805 (2013), Abstract;
FANCA and FANCC modulate TLR and p38 MAPK-dependent expression of IL-1β in macrophages: M.R. Garbati, et al.; Blood 122, 3197 (2013), Abstract;
Distinct TLR adjuvants differentially stimulate systemic and local innate immune responses in nonhuman primates: M. Kwissa, et al.; Blood 119, 2044 (2012), Abstract;
Interleukin-15-induced CD56+ myeloid dendritic cells combine potent tumor antigen presentation with direct tumoricidal potential. : S. Anguille, et al.; PLoS One 7, e51851 (2012), Application(s): Maturation of human dendritic cells, Abstract; Full Text
Immune response in the duck intestine following infection with low-pathogenic avian influenza viruses or stimulation with a Toll-like receptor 7 agonist administered orally: C. Volmer, et al.; J. Gen. Virol. 92, 534 (2011), Abstract;
The TLR7 agonist R848 alleviates allergic inflammation by targeting invariant NKT cells to produce IFN-gamma: F. Grela, et al.; J. Immunol. 186, 284 (2011), Abstract;
Treatment with the TLR7 agonist R848 induces regulatory T-cell-mediated suppression of established asthma symptoms: L. Pham Van, et al.; Eur. J. Immunol. 41, 1992 (2011), Abstract;
Differential induction of inflammatory cytokines by dendritic cells treated with novel TLR-agonist and cytokine based cocktails: targeting dendritic cells in autoimmunity: S.S. Jensen & M. Gad; J. Inflamm. 7, 37 (2010), Abstract;
Reciprocal regulation of activating and inhibitory Fc{gamma} receptors by TLR7/8 activation: implications for tumor immunotherapy: J.P. Butchar, et al.; Clin. Cancer Res. 16, 2065 (2010), Abstract; Full Text
Systemic Toll-like receptor stimulation suppresses experimental allergic asthma and autoimmune diabetes in NOD mice: A. Aumeunier, et al.; PLOS ONE 5, e11484 (2010), Abstract; Full Text
Toll-like receptor 7-triggered immune response in the lung mediates acute and long-lasting suppression of experimental asthma: C. Xirakia, et al.; Am. J. Respir. Crit. Care Med. 181, 1207 (2010), Abstract; Full Text
A novel polymorphism of the human CD40 receptor with enhanced function: A.L. Peters, et al.; Blood 112, 1863 (2008), Abstract;
Treatment of intravaginal HSV-2 infection in mice: a comparison of CpG oligodeoxynucleotides and resiquimod (R-848): M.J. McCluskie, et al.; Antiviral Res. 69, 77 (2006), Abstract;
Direct stimulation of human T cells via TLR5 and TLR7/8: flagellin and R-848 up-regulate proliferation and IFN-gamma production by memory CD4+ T cells: G. Caron, et al.; J. Immunol. 175, 1551 (2005), Abstract; Full Text
TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848): R.D. Weeratna, et al.; Vaccine 23, 5263 (2005), Abstract;
Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses: J.J. Wu, et al.; Antiviral Res. 64, 79 (2004), Abstract;
Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848: M. Jurk, et al.; Nat. Immunol. 3, 499 (2002), Abstract;
Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway: H. Hemmi, et al.; Nat. Immunol. 3, 196 (2002), Abstract;
The immune response modifier resiquimod mimics CD40-induced B cell activation: G.A. Bishop, et al.; Cell. Immunol. 208, 9 (2001), Abstract;

Related Literature

Innovative Products to Analyze Immunological Disorders
Innovative Products to Analyze Immunological Disorders
Download as PDF

All new literature pieces

Recommend this page

For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2020 Enzo Life Sciences, Inc.,